Aptar CSP Technologies, part of AptarGroup, announced the expansion of its service offerings with the launch of a CGMP-compliant manufacturing facility in New Jersey.
The new site will support clinical packaging for oral solid dose (OSD) and capsule-based dry powder inhaler (DPI) drugs. It will also address growing market demand for enhanced drug stability and nitrosamine risk mitigation utilizing Aptar CSP’s proprietary Activ-Blister technology. The technology integrates an engineered active film material into thermoform and cold-form blister packaging configurations, creating a microclimate that protects individual doses from moisture, oxygen, VOCs, and degradation, including reducing the risk of N-nitrosamine formation.
The new site, which is the result of a collaboration with CDMO MOD3 Pharma (formerly Enteris BioPharma), will offer services including R&D support, phase 1 and 2 clinical material manufacturing, full CMC package, stability studies, and clinical supply management.
“Launching this cGMP facility reinforces our commitment to delivering streamlined access to innovative active material science technologies for patients and pharmaceutical partners,” said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. “By offering early-stage clinical services with custom-designed equipment, we simplify adoption, eliminate implementation barriers, and help avoid lengthy reformulation or repackaging efforts.”